目的 探讨豨莶通栓胶囊联合丁苯酞软胶囊治疗急性脑梗死的临床疗效。方法 选取2019年2月-2020年2月南开大学附属医院收治的92例急性脑梗死患者作为研究对象，按照随机数字表法将全部患者分为对照组和治疗组，每组各46例。对照组口服丁苯酞软胶囊，2粒/次，3次/d。治疗组在对照组治疗的基础上口服豨莶通栓胶囊，3粒/次，3次/d。两组患者连续治疗4周。观察两组的临床疗效，比较两组的NIHSS评分、白细胞介素-6（IL-6）、同型半胱氨酸（Hcy）、脑源性神经营养因子（BDNF）、中枢神经特异蛋白（S100β）、血浆比黏度、纤维蛋白原、D-二聚体。结果 治疗后，治疗组的总有效率（93.48%）明显比对照组（78.26%）高，差异有统计学意义（P<0.05）。治疗后，两组的血浆比黏度、纤维蛋白原、D-二聚体显著降低（P<0.05）；治疗后，治疗组的血浆比黏度、纤维蛋白原、D-二聚体均低于对照组，差异具有统计学意义（P<0.05）。治疗后，两组的IL-6、Hcy、BDNF、S100β蛋白显著降低（P<0.05）；治疗后，治疗组的IL-6、Hcy、BDNF、S100β蛋白低于对照组，差异有统计学意义（P<0.05）。治疗后，两组患者的NIHSS评分均显著降低（P<0.05），以治疗组NIHSS评分降低的更明显（P<0.05）。结论 豨莶通栓胶囊联合丁苯酞软胶囊治疗急性脑梗死具有较好的疗效，能减轻神经组织的炎性损伤，改善血液流变学水平，减轻神经功能缺损程度。

Objective To investigate the clinical effect of Xixian Tongshuan Capsules combined with Butylphthalide Soft Capsules in treatment of acute cerebral infarction. Methods Patients (92 cases) with acute cerebral infarction in the Affiliated Hospital of Nankai University from February 2019 to February 2020 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Butylphthalide Soft Capsules, 2 grains/time, three times daily. Patients in the treatment group were po administered with Xixian Tongshuan Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and NIHSS scores, IL-6, Hcy, BDNF, S100β protein, plasma specific viscosity, fibrinogen, and D-dimer in two groups were compared. Results After treatment, the total effective rate of the treatment group (93.48%) was significantly higher than that of the control group (78.26%), and the difference was statistically significant (P<0.05). After treatment, the plasma specific viscosity, fibrinogen, and D-dimer in two groups were significantly decreased (P<0.05). After treatment, the plasma specific viscosity, fibrinogen, and D-dimer in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of IL-6, Hcy, BDNF, and S100β protein in two groups were significantly decreased (P<0.05). After treatment, the levels of IL-6, Hcy, BDNF, and S100β protein in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the NIHSS scores of two groups were significantly decreased (P<0.05), and the NIHSS score of the treatment group was significantly lower than that of the control group (P<0.05). Conclusion Xixian Tongshuan Capsules combined with Butylphthalide Soft Capsules has clinical curative effect in treatment of acute cerebral infarction, can reduce the inflammatory injury of nerve tissue, improve the level of hemorheology, and reduce the degree of nerve function defect.

R971

天津市滨海新区卫生局科技项目（2014BWKY013）